IL1B and Castleman disease: At this moment, various therapies targeting pro-inflammatory cytokines have been approved and have demonstrated a beneficial effect in other pathologies, such as: using Etanercept, Adalimumab, and Infliximab against TNF-α in inflammatory intestinal and rheumatological diseases [27,28,57]; usingTocilizumab against IL-6 in Crohn’s disease and rheumatology diseases, and also Siltuximab with Elsilimomab when directed against IL-6 in Castleman’s disease [58,59]; using Canakinumab against IL-1β in patients with cryopyrin-associated periodic syndromes [60,61].